All dermatologists will agree that it works well to treat local areas such as spot, birthmarks and in general hyper pigmentation
Constipation specifically appears in about 20% of semaglutide patients and typically resolves without stopping the medication
Although semaglutide is approved for treatment of obesity, tirzepatide and CagriSema are still in clinical trials and not yet approved for obesity
These evidences all suggest that the action of GLP-1R in liver cells may be directly stimulated by ligand-receptor action
Clinically, liraglutide could reduce body weight and hepatic fatty accumulation (Zhou et al., 2019)
Average Weight Loss on Semaglutide In the main clinical trial that supported semaglutide's approval for weight management (the STEP 1 trial), adults who took the 2.4 mg weekly dose lost, on average, about 15% of their body weight over 68 weeks, compared with a much smaller amount in the placebo group